1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. ROIVANT SCIENCES LTD
Roivant Sciences Ltd
XNAS: ROIV
Download real time
39.77 -0.21 (-0.53%)
174.28% Gain from 52W Low
32.2M
XNAS Volume
High volume today

XNAS 18 Sep, 2026 5:30 PM (EDT)

Watchlist

Portfolio

Alert


Insider Trading disclosures for Roivant Sciences Ltd

The latest disclosure was made by Meghan M. Fitzgerald in Roivant Sciences Ltd where a trade of 4,712 Common Shares done at an average price of $39.7 was reported to US exchanges on Sept. 15, 2026.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Meghan M. Fitzgerald Director Sale of securities on an exchange or to another person at price $ 39.68 per share. 15 Sep 2026 4,712 36,508 - 39.7 186,972 Common Shares
Meghan M. Fitzgerald Director Sale of securities on an exchange or to another person at price $ 40.45 per share. 15 Sep 2026 400 36,108 - 40.5 16,180 Common Shares
Melissa B. Epperly Director Sale of securities on an exchange or to another person at price $ 40.38 per share. 15 Sep 2026 600 9,900 - 40.4 24,228 Common Shares
Melissa B. Epperly Director Sale of securities on an exchange or to another person at price $ 39.65 per share. 15 Sep 2026 4,338 10,500 - 39.7 172,002 Common Shares
James C. Momtazee Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 40.94 per share. 10 Sep 2026 2,905 106,905 - 40.9 118,931 Common Shares
Meghan M. Fitzgerald Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 40.94 per share. 10 Sep 2026 1,743 41,220 - 40.9 71,358 Common Shares
Ilan Oren Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 40.94 per share. 10 Sep 2026 2,378 118,626 - 40.9 97,355 Common Shares
Melissa B. Epperly Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 40.94 per share. 10 Sep 2026 2,179 14,838 - 40.9 89,208 Common Shares
Daniel Gold Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 40.94 per share. 10 Sep 2026 5,133 8,960,761 - 40.9 210,145 Common Shares
Meghan M. Fitzgerald Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.80 per share. 08 Sep 2026 20,000 62,963 - 8.8 176,000 Common Shares
Meghan M. Fitzgerald Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 08 Sep 2026 20,000 18,578 - - Stock Option (Right to Buy)
Meghan M. Fitzgerald Director Sale of securities on an exchange or to another person at price $ 39.90 per share. 08 Sep 2026 20,000 42,963 - 39.9 798,000 Common Shares
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 35.63 per share. 28 Aug 2026 166,182 1,632,972 - 35.6 5,921,065 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 28 Aug 2026 200,000 1,799,154 - 3.9 770,000 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 28 Aug 2026 200,000 3,844,834 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 36.44 per share. 28 Aug 2026 33,818 1,599,154 - 36.4 1,232,328 Common Shares
Eric Venker President & Immunovant CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.84 per share. 20 Aug 2026 13,909 1,599,154 - 36.8 512,408 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.84 per share. 20 Aug 2026 5,749 271,810 - 36.8 211,793 Common Shares
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Aug 2026 17,519 13,369,119 - - Stock Option (Right to Buy)
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Aug 2026 172,899 13,386,638 - - Stock Option (Right to Buy)
Mayukh Sukhatme Director, President & CIO Sale of securities on an exchange or to another person at price $ 36.48 per share. 19 Aug 2026 144,756 18,630,739 - 36.5 5,280,699 Common Shares
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 19 Aug 2026 144,756 18,775,495 - 3.9 557,311 Common Shares
Mayukh Sukhatme Director, President & CIO Sale of securities on an exchange or to another person at price $ 37.30 per share. 19 Aug 2026 17,519 18,630,739 - 37.3 653,459 Common Shares
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 19 Aug 2026 17,519 18,648,258 - 3.8 67,448 Common Shares
Mayukh Sukhatme Director, President & CIO Sale of securities on an exchange or to another person at price $ 37.17 per share. 19 Aug 2026 172,899 18,630,739 - 37.2 6,426,656 Common Shares
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 19 Aug 2026 172,899 18,803,638 - 3.8 665,661 Common Shares
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Aug 2026 144,756 13,224,363 - - Stock Option (Right to Buy)
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 14 Aug 2026 243,177 18,873,916 - 3.8 936,231 Common Shares
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Aug 2026 136,942 13,559,537 - - Common Shares
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Aug 2026 284,707 13,696,479 - - Common Shares
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Aug 2026 243,177 13,981,186 - - Common Shares
Mayukh Sukhatme Director, President & CIO Sale of securities on an exchange or to another person at price $ 37.18 per share. 14 Aug 2026 31,801 18,630,739 - 37.2 1,182,361 Common Shares
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 14 Aug 2026 31,801 18,662,540 - 3.9 122,434 Common Shares
Mayukh Sukhatme Director, President & CIO Sale of securities on an exchange or to another person at price $ 36.59 per share. 14 Aug 2026 105,141 18,630,739 - 36.6 3,847,109 Common Shares
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 14 Aug 2026 105,141 18,735,880 - 3.9 404,793 Common Shares
Mayukh Sukhatme Director, President & CIO Sale of securities on an exchange or to another person at price $ 36.25 per share. 14 Aug 2026 284,707 18,630,739 - 36.3 10,320,629 Common Shares
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 14 Aug 2026 284,707 18,915,446 - 3.9 1,096,122 Common Shares
Mayukh Sukhatme Director, President & CIO Sale of securities on an exchange or to another person at price $ 36.23 per share. 14 Aug 2026 243,177 18,630,739 - 36.2 8,810,303 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 27 Jul 2026 200,000 4,044,834 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 34.95 per share. 27 Jul 2026 200,000 1,613,063 - 35.0 6,990,000 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 27 Jul 2026 200,000 1,813,063 - 3.9 770,000 Common Shares
James C. Momtazee Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Jul 2026 405 109,810 - 0 Common Shares
Ilan Oren Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Jul 2026 775 121,004 - 0 Common Shares
Melissa B. Epperly Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Jul 2026 543 17,017 - 0 Common Shares
Meghan M. Fitzgerald Director Sale of securities on an exchange or to another person at price $ 34.90 per share. 30 Jun 2026 10,000 42,963 - 34.9 349,000 Common Shares
Meghan M. Fitzgerald Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 30 Jun 2026 10,000 38,578 - - Stock Option (Right to Buy)
Meghan M. Fitzgerald Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.80 per share. 30 Jun 2026 10,000 52,963 - 8.8 88,000 Common Shares
Frank M. Torti President and Vant Chair Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.39 per share. 30 Jun 2026 40,310 13,536,202 - 35.4 1,426,571 Common Shares
Matthew Gline Director, CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.39 per share. 30 Jun 2026 76,171 16,659,945 - 35.4 2,695,692 Common Shares
Mayukh Sukhatme Director, President & CIO Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.39 per share. 30 Jun 2026 46,878 18,630,739 - 35.4 1,659,012 Common Shares
Melissa B. Epperly Director Sale of securities on an exchange or to another person at price $ 34.71 per share. 29 Jun 2026 2,748 16,474 - 34.7 95,383 Common Shares
Melissa B. Epperly Director Sale of securities on an exchange or to another person at price $ 34.32 per share. 29 Jun 2026 15,002 19,222 - 34.3 514,869 Common Shares
Melissa B. Epperly Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.46 per share. 29 Jun 2026 17,750 34,224 - 4.5 79,165 Common Shares
Melissa B. Epperly Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 29 Jun 2026 17,750 169,166 - - Stock Option (Right to Buy)
Keith Manchester Director Sale of securities on an exchange or to another person at price $ 33.92 per share. 26 Jun 2026 300,783 14,826,546 - 33.9 10,202,559 Common Shares
Keith Manchester Director Sale of securities on an exchange or to another person at price $ 35.45 per share. 26 Jun 2026 200,000 1,748,403 - 35.5 7,090,000 Common Shares
Keith Manchester Director Sale of securities on an exchange or to another person at price $ 34.59 per share. 26 Jun 2026 600,000 13,701,546 - 34.6 20,754,000 Common Shares
Keith Manchester Director Sale of securities on an exchange or to another person at price $ 35.28 per share. 26 Jun 2026 12,380 13,689,166 - 35.3 436,766 Common Shares
Keith Manchester Director Sale of securities on an exchange or to another person at price $ 34.44 per share. 26 Jun 2026 200,000 14,301,546 - 34.4 6,888,000 Common Shares
Keith Manchester Director Sale of securities on an exchange or to another person at price $ 34.07 per share. 26 Jun 2026 325,000 14,501,546 - 34.1 11,072,750 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 34.07 per share. 26 Jun 2026 325,000 14,501,546 - 34.1 11,072,750 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 35.28 per share. 26 Jun 2026 12,380 13,689,166 - 35.3 436,766 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 34.59 per share. 26 Jun 2026 600,000 13,701,546 - 34.6 20,754,000 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 34.44 per share. 26 Jun 2026 200,000 14,301,546 - 34.4 6,888,000 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 33.92 per share. 26 Jun 2026 300,783 14,826,546 - 33.9 10,202,559 Common Shares
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 25 Jun 2026 500,000 19,177,617 - 3.9 1,925,000 Common Shares
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 25 Jun 2026 500,000 14,224,363 - - Stock Option (Right to Buy)
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 25 Jun 2026 500,000 14,724,363 - - Stock Option (Right to Buy)
Mayukh Sukhatme Director, President & CIO Sale of securities on an exchange or to another person at price $ 34.08 per share. 25 Jun 2026 500,000 18,677,617 - 34.1 17,040,000 Common Shares
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 25 Jun 2026 500,000 19,177,617 - 3.9 1,925,000 Common Shares
Mayukh Sukhatme Director, President & CIO Sale of securities on an exchange or to another person at price $ 34.13 per share. 25 Jun 2026 500,000 18,677,617 - 34.1 17,065,000 Common Shares
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 33.51 per share. 24 Jun 2026 46,234 1,613,063 - 33.5 1,549,301 Common Shares
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 33.05 per share. 24 Jun 2026 153,766 1,659,297 - 33.0 5,081,966 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 24 Jun 2026 200,000 1,813,063 - 3.9 770,000 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 24 Jun 2026 200,000 4,244,834 - - Stock Option (Right to Buy)
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.43 per share. 20 Jun 2026 2,129 276,420 - 31.4 66,914 Common Shares
Jennifer Humes Chief Accounting Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.43 per share. 20 Jun 2026 3,582 109,782 - 31.4 112,582 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 20 May 2026 200,000 4,444,834 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 30.27 per share. 20 May 2026 200,000 1,613,063 - 30.3 6,054,000 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 20 May 2026 200,000 1,813,063 - 3.9 770,000 Common Shares
Eric Venker President & Immunovant CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.41 per share. 20 May 2026 34,483 1,613,063 - 32.4 1,117,594 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.41 per share. 20 May 2026 18,962 278,549 - 32.4 614,558 Common Shares
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 29.59 per share. 20 Apr 2026 200,000 1,647,546 - 29.6 5,918,000 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 20 Apr 2026 200,000 1,847,546 - 3.9 770,000 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 20 Apr 2026 200,000 4,644,834 - - Stock Option (Right to Buy)
Richard Pulik CFO Grant, award, or other acquisition of securities at price $ 0.00 per share. 20 Apr 2026 84,026 84,026 - - Stock Option (Right to Buy)
Richard Pulik CFO Grant, award, or other acquisition of securities at price $ 0.00 per share. 20 Apr 2026 60,644 297,511 - 0 Common Shares
Jennifer Humes Chief Accounting Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 20 Apr 2026 29,173 113,364 - 0 Common Shares
Jennifer Humes Chief Accounting Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 20 Apr 2026 27,157 27,157 - - Stock Option (Right to Buy)
James C. Momtazee Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.83 per share. 17 Apr 2026 94 109,405 - 29.8 2,804 Common Shares
James C. Momtazee Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Apr 2026 469 109,499 - 0 Common Shares
Ilan Oren Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Apr 2026 896 120,324 - 0 Common Shares
Ilan Oren Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.83 per share. 17 Apr 2026 95 120,229 - 29.8 2,834 Common Shares
Melissa B. Epperly Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Apr 2026 670 16,474 - 0 Common Shares
Matthew Gline Director, CEO Sale of securities on an exchange or to another person at price $ 29.16 per share. 16 Apr 2026 289,774 16,736,116 - 29.2 8,449,810 Common Shares
Jennifer Humes Chief Accounting Officer Sale of securities on an exchange or to another person at price $ 28.37 per share. 08 Apr 2026 13,538 84,191 - 28.4 384,073 Common Shares
Frank M. Torti President and Vant Chair Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.70 per share. 31 Mar 2026 160,035 13,576,512 - 27.7 4,432,970 Common Shares
Matthew Gline Director, CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 30 Mar 2026 97,319 17,384,400 - - Common Shares
Matthew Gline Director, CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 30 Mar 2026 2,178,150 0 - - Capped Value Appreciation Rights
Matthew Gline Director, CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.70 per share. 30 Mar 2026 304,684 17,025,890 - 27.7 8,439,747 Common Shares
Matthew Gline Director, CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.41 per share. 30 Mar 2026 53,826 17,330,574 - 26.4 1,421,545 Common Shares
Mayukh Sukhatme Director, President & CIO Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.41 per share. 30 Mar 2026 29,809 18,865,129 - 26.4 787,256 Common Shares
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 30 Mar 2026 1,306,889 0 - - Capped Value Appreciation Rights
Mayukh Sukhatme Director, President & CIO Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.70 per share. 30 Mar 2026 187,512 18,677,617 - 27.7 5,194,082 Common Shares
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 30 Mar 2026 58,391 18,894,938 - - Common Shares
Meghan M. Fitzgerald Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 26 Mar 2026 70,000 48,578 - - Stock Option (Right to Buy)
Meghan M. Fitzgerald Director Sale of securities on an exchange or to another person at price $ 27.45 per share. 26 Mar 2026 70,000 42,963 - 27.5 1,921,500 Common Shares
Meghan M. Fitzgerald Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.80 per share. 26 Mar 2026 70,000 112,963 - 8.8 616,000 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.70 per share. 20 Mar 2026 1,546 236,867 - 27.7 42,824 Common Shares
Jennifer Humes Chief Accounting Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.70 per share. 20 Mar 2026 14,526 97,729 - 27.7 402,370 Common Shares
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 28.24 per share. 17 Mar 2026 200,000 1,647,546 - 28.2 5,648,000 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 17 Mar 2026 200,000 4,844,834 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 17 Mar 2026 200,000 1,847,546 - 3.9 770,000 Common Shares
Melissa B. Epperly Director Sale of securities on an exchange or to another person at price $ 28.68 per share. 16 Mar 2026 41,861 15,804 - 28.7 1,200,573 Common Shares
Eric Venker President & Immunovant CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.15 per share. 20 Feb 2026 7,051 1,647,546 - 27.2 191,435 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.15 per share. 20 Feb 2026 1,000 238,413 - 27.2 27,150 Common Shares
Frank M. Torti President and Vant Chair Sale of securities on an exchange or to another person at price $ 27.51 per share. 19 Feb 2026 587,390 13,736,547 - 27.5 16,159,099 Common Shares
Frank M. Torti President and Vant Chair Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 19 Feb 2026 587,390 14,323,937 - 3.9 2,261,452 Common Shares
Frank M. Torti President and Vant Chair Sale of securities on an exchange or to another person at price $ 27.15 per share. 19 Feb 2026 1,012,610 13,736,547 - 27.2 27,492,362 Common Shares
Frank M. Torti President and Vant Chair Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 19 Feb 2026 1,012,610 14,749,157 - 3.9 3,898,549 Common Shares
Frank M. Torti President and Vant Chair Sale of securities on an exchange or to another person at price $ 27.42 per share. 19 Feb 2026 1,400,000 13,736,547 - 27.4 38,388,000 Common Shares
Frank M. Torti President and Vant Chair Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 19 Feb 2026 1,400,000 15,136,547 - 3.9 5,390,000 Common Shares
Frank M. Torti President and Vant Chair Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Feb 2026 587,390 3,026,184 - - Stock Option (Right to Buy)
Frank M. Torti President and Vant Chair Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Feb 2026 1,012,610 3,613,574 - - Stock Option (Right to Buy)
Frank M. Torti President and Vant Chair Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Feb 2026 1,400,000 4,626,184 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 26.49 per share. 13 Feb 2026 200,000 1,654,597 - 26.5 5,298,000 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 13 Feb 2026 200,000 1,854,597 - 3.9 770,000 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Feb 2026 200,000 5,044,834 - - Stock Option (Right to Buy)
Keith Manchester Director Sale of securities on an exchange or to another person at price $ 26.50 per share. 11 Feb 2026 225,000 15,127,329 - 26.5 5,962,500 Common Shares
Keith Manchester Director Sale of securities on an exchange or to another person at price $ 26.76 per share. 11 Feb 2026 275,000 15,503,113 - 26.8 7,359,000 Common Shares
Keith Manchester Director Sale of securities on an exchange or to another person at price $ 26.72 per share. 11 Feb 2026 150,000 15,778,113 - 26.7 4,008,000 Common Shares
Keith Manchester Director Sale of securities on an exchange or to another person at price $ 26.67 per share. 11 Feb 2026 425,000 15,928,113 - 26.7 11,334,750 Common Shares
Keith Manchester Director Sale of securities on an exchange or to another person at price $ 26.49 per share. 11 Feb 2026 150,784 15,352,329 - 26.5 3,994,268 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 26.76 per share. 11 Feb 2026 275,000 15,503,113 - 26.8 7,359,000 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 26.72 per share. 11 Feb 2026 150,000 15,778,113 - 26.7 4,008,000 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 26.50 per share. 11 Feb 2026 225,000 15,127,329 - 26.5 5,962,500 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 26.67 per share. 11 Feb 2026 425,000 15,928,113 - 26.7 11,334,750 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 26.49 per share. 11 Feb 2026 150,784 15,352,329 - 26.5 3,994,268 Common Shares
Mayukh Sukhatme Director, President & CIO Sale of securities on an exchange or to another person at price $ 26.47 per share. 09 Feb 2026 339,441 19,148,664 - 26.5 8,985,003 Common Shares
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.68 per share. 09 Feb 2026 651,558 19,488,105 - 12.7 8,261,755 Common Shares
Mayukh Sukhatme Director, President & CIO Other type of transaction at price $ 26.47 per share. 09 Feb 2026 312,117 18,836,547 - 26.5 8,261,737 Common Shares
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 09 Feb 2026 651,558 0 - - Stock Option (Right to Buy)
James C. Momtazee Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.98 per share. 20 Jan 2026 122 109,030 - 23.0 2,804 Common Shares
James C. Momtazee Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 20 Jan 2026 609 109,152 - 0 Common Shares
Ilan Oren Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.98 per share. 20 Jan 2026 124 119,428 - 23.0 2,850 Common Shares
Ilan Oren Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 20 Jan 2026 1,164 119,552 - 0 Common Shares
Melissa B. Epperly Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.98 per share. 20 Jan 2026 54 57,665 - 23.0 1,241 Common Shares
Melissa B. Epperly Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 20 Jan 2026 815 57,719 - 0 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 12 Jan 2026 200,000 1,854,597 - 3.9 770,000 Common Shares
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 21.92 per share. 12 Jan 2026 200,000 1,654,597 - 21.9 4,384,000 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 12 Jan 2026 200,000 5,244,834 - - Stock Option (Right to Buy)
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.68 per share. 29 Dec 2025 748,358 19,584,905 - 12.7 9,489,179 Common Shares
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 29 Dec 2025 748,358 555,840 - - Stock Option (Right to Buy)
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 29 Dec 2025 2,449,877 95,718 - - Stock Option (Right to Buy)
Mayukh Sukhatme Director, President & CIO Other type of transaction at price $ 21.71 per share. 29 Dec 2025 1,430,882 18,836,547 - 21.7 31,064,448 Common Shares
Mayukh Sukhatme Director, President & CIO Sale of securities on an exchange or to another person at price $ 21.71 per share. 29 Dec 2025 1,018,995 20,267,429 - 21.7 22,122,381 Common Shares
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.68 per share. 29 Dec 2025 2,449,877 21,286,424 - 12.7 31,064,440 Common Shares
Mayukh Sukhatme Director, President & CIO Other type of transaction at price $ 21.74 per share. 29 Dec 2025 436,485 18,836,547 - 21.7 9,489,184 Common Shares
Mayukh Sukhatme Director, President & CIO Sale of securities on an exchange or to another person at price $ 21.74 per share. 29 Dec 2025 311,873 19,273,032 - 21.7 6,780,119 Common Shares
Frank M. Torti President and Vant Chair Grant, award, or other acquisition of securities at price $ 22.45 per share. 23 Dec 2025 175,380 13,911,927 - 22.5 3,937,281 Common Shares
Frank M. Torti President and Vant Chair Gift of securities by or to the insider at price $ 0.00 per share. 23 Dec 2025 110,489 13,736,547 - 0 Common Shares
Frank M. Torti President and Vant Chair Other type of transaction at price $ 22.47 per share. 23 Dec 2025 64,891 13,847,036 - 22.5 1,458,101 Common Shares
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 22.53 per share. 23 Dec 2025 75,000 1,654,597 - 22.5 1,689,750 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 23 Dec 2025 117,848 1,729,597 - 3.9 453,715 Common Shares
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 22.45 per share. 23 Dec 2025 200,000 1,611,749 - 22.5 4,490,000 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 23 Dec 2025 313,841 1,811,749 - 3.9 1,208,288 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 23 Dec 2025 313,841 5,562,682 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 23 Dec 2025 117,848 5,444,834 - - Stock Option (Right to Buy)
Richard Pulik CFO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 23 Dec 2025 260,000 646,144 - 3.9 1,001,000 Common Shares
Richard Pulik CFO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 23 Dec 2025 260,000 740,000 - - Stock Option (Right to Buy)
Richard Pulik CFO Sale of securities on an exchange or to another person at price $ 22.39 per share. 23 Dec 2025 146,731 239,413 - 22.4 3,285,307 Common Shares
Richard Pulik CFO Sale of securities on an exchange or to another person at price $ 22.45 per share. 23 Dec 2025 260,000 386,144 - 22.5 5,837,000 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.41 per share. 20 Dec 2025 2,129 386,144 - 22.4 47,711 Common Shares
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.68 per share. 17 Dec 2025 59,513 18,896,060 - 12.7 754,625 Common Shares
Mayukh Sukhatme Director, President & CIO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 17 Dec 2025 59,513 1,304,198 - - Common Shares
Mayukh Sukhatme Director, President & CIO Other type of transaction at price $ 23.09 per share. 17 Dec 2025 32,682 18,836,547 - 23.1 754,627 Common Shares
Mayukh Sukhatme Director, President & CIO Sale of securities on an exchange or to another person at price $ 23.09 per share. 17 Dec 2025 26,831 18,869,229 - 23.1 619,528 Common Shares
Keith Manchester Director Sale of securities on an exchange or to another person at price $ 23.02 per share. 16 Dec 2025 155,076 16,542,651 - 23.0 3,569,850 Common Shares
Keith Manchester Director Sale of securities on an exchange or to another person at price $ 23.05 per share. 16 Dec 2025 432,718 16,697,727 - 23.1 9,974,150 Common Shares
Keith Manchester Director Sale of securities on an exchange or to another person at price $ 23.08 per share. 16 Dec 2025 642,282 17,130,445 - 23.1 14,823,869 Common Shares
Keith Manchester Director Sale of securities on an exchange or to another person at price $ 22.93 per share. 16 Dec 2025 275,000 17,772,727 - 22.9 6,305,750 Common Shares
Keith Manchester Director Sale of securities on an exchange or to another person at price $ 23.17 per share. 16 Dec 2025 189,538 16,353,113 - 23.2 4,391,595 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 23.05 per share. 16 Dec 2025 432,718 16,697,727 - 23.1 9,974,150 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 23.17 per share. 16 Dec 2025 189,538 16,353,113 - 23.2 4,391,595 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 23.08 per share. 16 Dec 2025 642,282 17,130,445 - 23.1 14,823,869 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 22.93 per share. 16 Dec 2025 275,000 17,772,727 - 22.9 6,305,750 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 23.02 per share. 16 Dec 2025 155,076 16,542,651 - 23.0 3,569,850 Common Shares
Matthew Gline Director, CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 15 Dec 2025 2,272,852 0 - - Stock Option (Right to Buy)
Matthew Gline Director, CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 15 Dec 2025 1,363,711 0 - - Stock Option (Right to Buy)
Matthew Gline Director, CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 15 Dec 2025 234,096 0 - - Stock Option (Right to Buy)
Matthew Gline Director, CEO Other type of transaction at price $ 21.68 per share. 15 Dec 2025 1,329,325 17,287,081 - 21.7 28,819,766 Common Shares
Matthew Gline Director, CEO Sale of securities on an exchange or to another person at price $ 21.68 per share. 15 Dec 2025 943,527 18,616,406 - 21.7 20,455,665 Common Shares
Matthew Gline Director, CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.68 per share. 15 Dec 2025 2,272,852 19,559,933 - 12.7 28,819,763 Common Shares
Matthew Gline Director, CEO Other type of transaction at price $ 21.68 per share. 15 Dec 2025 797,595 17,287,081 - 21.7 17,291,860 Common Shares
Matthew Gline Director, CEO Sale of securities on an exchange or to another person at price $ 21.68 per share. 15 Dec 2025 566,116 18,084,676 - 21.7 12,273,395 Common Shares
Matthew Gline Director, CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.68 per share. 15 Dec 2025 1,363,711 18,650,792 - 12.7 17,291,855 Common Shares
Matthew Gline Director, CEO Other type of transaction at price $ 21.68 per share. 15 Dec 2025 3,739 17,287,081 - 21.7 81,062 Common Shares
Matthew Gline Director, CEO Sale of securities on an exchange or to another person at price $ 21.68 per share. 15 Dec 2025 230,357 17,290,820 - 21.7 4,994,140 Common Shares
Matthew Gline Director, CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.06 per share. 15 Dec 2025 234,096 17,521,177 - 4.1 950,430 Common Shares
Vivek Ramaswamy Ten Percent Owner Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.68 per share. 11 Dec 2025 1,869,691 35,523,447 - 12.7 23,707,682 Common Shares
Vivek Ramaswamy Ten Percent Owner Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 11 Dec 2025 832,453 22,150,227 - - Stock Option (Right to Buy)
Vivek Ramaswamy Ten Percent Owner Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 11 Dec 2025 4,672,724 22,982,680 - - Stock Option (Right to Buy)
Vivek Ramaswamy Ten Percent Owner Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 11 Dec 2025 1,869,691 27,655,404 - - Stock Option (Right to Buy)
Vivek Ramaswamy Ten Percent Owner Other type of transaction at price $ 22.05 per share. 11 Dec 2025 478,708 33,653,755 - 22.0 10,555,511 Common Shares
Vivek Ramaswamy Ten Percent Owner Sale of securities on an exchange or to another person at price $ 22.05 per share. 11 Dec 2025 353,745 34,132,463 - 22.0 7,800,077 Common Shares
Vivek Ramaswamy Ten Percent Owner Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.68 per share. 11 Dec 2025 832,453 34,486,208 - 12.7 10,555,504 Common Shares
Vivek Ramaswamy Ten Percent Owner Other type of transaction at price $ 21.96 per share. 11 Dec 2025 2,696,866 33,653,755 - 22.0 59,223,177 Common Shares
Vivek Ramaswamy Ten Percent Owner Sale of securities on an exchange or to another person at price $ 21.96 per share. 11 Dec 2025 1,975,858 36,350,621 - 22.0 43,389,842 Common Shares
Vivek Ramaswamy Ten Percent Owner Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.68 per share. 11 Dec 2025 4,672,724 38,326,479 - 12.7 59,250,140 Common Shares
Vivek Ramaswamy Ten Percent Owner Other type of transaction at price $ 21.64 per share. 11 Dec 2025 1,095,550 33,653,755 - 21.6 23,707,702 Common Shares
Vivek Ramaswamy Ten Percent Owner Sale of securities on an exchange or to another person at price $ 21.64 per share. 11 Dec 2025 774,142 34,749,305 - 21.6 16,752,433 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 09 Dec 2025 200,000 5,876,523 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 20.85 per share. 09 Dec 2025 200,000 1,497,908 - 20.9 4,170,000 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 09 Dec 2025 200,000 1,697,908 - 3.9 770,000 Common Shares
Eric Venker President & Immunovant CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.27 per share. 20 Nov 2025 7,051 1,497,908 - 20.3 142,924 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.27 per share. 20 Nov 2025 1,235 388,273 - 20.3 25,033 Common Shares
Keith Manchester Director Sale of securities on an exchange or to another person at price $ 20.25 per share. 19 Nov 2025 850,000 18,497,727 - 20.3 17,212,500 Common Shares
Keith Manchester Director Sale of securities on an exchange or to another person at price $ 20.24 per share. 19 Nov 2025 175,000 18,047,727 - 20.2 3,542,000 Common Shares
Keith Manchester Director Sale of securities on an exchange or to another person at price $ 20.16 per share. 19 Nov 2025 125,000 18,222,727 - 20.2 2,520,000 Common Shares
Keith Manchester Director Sale of securities on an exchange or to another person at price $ 20.20 per share. 19 Nov 2025 150,000 18,347,727 - 20.2 3,030,000 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 20.20 per share. 19 Nov 2025 150,000 18,347,727 - 20.2 3,030,000 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 20.24 per share. 19 Nov 2025 175,000 18,047,727 - 20.2 3,542,000 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 20.16 per share. 19 Nov 2025 125,000 18,222,727 - 20.2 2,520,000 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 20.25 per share. 19 Nov 2025 850,000 18,497,727 - 20.3 17,212,500 Common Shares
Vivek Ramaswamy Ten Percent Owner Sale of securities on an exchange or to another person at price $ 20.33 per share. 13 Nov 2025 1,027,670 34,193,406 - 20.3 20,892,531 Common Shares
Vivek Ramaswamy Ten Percent Owner Sale of securities on an exchange or to another person at price $ 20.51 per share. 13 Nov 2025 539,650 33,653,756 - 20.5 11,068,222 Common Shares
Vivek Ramaswamy Ten Percent Owner Sale of securities on an exchange or to another person at price $ 20.81 per share. 13 Nov 2025 287,283 35,221,076 - 20.8 5,978,359 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 07 Nov 2025 200,000 6,076,523 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 07 Nov 2025 200,000 1,704,959 - 3.9 770,000 Common Shares
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 20.22 per share. 07 Nov 2025 200,000 1,504,959 - 20.2 4,044,000 Common Shares
James C. Momtazee Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 20 Oct 2025 789 108,701 - 0 Common Shares
James C. Momtazee Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.74 per share. 20 Oct 2025 158 108,543 - 17.7 2,803 Common Shares
Ilan Oren Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 20 Oct 2025 1,507 118,669 - 0 Common Shares
Ilan Oren Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.74 per share. 20 Oct 2025 281 118,388 - 17.7 4,985 Common Shares
Melissa B. Epperly Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 20 Oct 2025 1,056 56,904 - 0 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.85 per share. 15 Oct 2025 414,683 1,919,642 - 15.9 6,572,726 Common Shares
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 17.06 per share. 15 Oct 2025 118,418 1,504,959 - 17.1 2,020,211 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 15 Oct 2025 414,683 436,700 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 15 Oct 2025 318,282 118,418 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 15 Oct 2025 118,418 0 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.85 per share. 15 Oct 2025 118,418 1,623,377 - 15.8 1,876,925 Common Shares
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 17.05 per share. 15 Oct 2025 318,282 1,504,959 - 17.0 5,426,708 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.85 per share. 15 Oct 2025 318,282 1,823,241 - 15.9 5,044,770 Common Shares
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 16.93 per share. 15 Oct 2025 414,683 1,504,959 - 16.9 7,020,583 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.85 per share. 09 Oct 2025 104,940 1,609,899 - 15.9 1,663,299 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 09 Oct 2025 104,940 872,110 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 09 Oct 2025 20,727 851,383 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 16.25 per share. 09 Oct 2025 20,727 1,504,959 - 16.3 336,814 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.85 per share. 09 Oct 2025 20,727 1,525,686 - 15.9 328,523 Common Shares
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 16.30 per share. 09 Oct 2025 104,940 1,504,959 - 16.3 1,710,522 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.45 per share. 06 Oct 2025 24,900 1,657,214 - 7.5 185,505 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.85 per share. 06 Oct 2025 127,355 1,632,314 - 15.9 2,018,577 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 06 Oct 2025 127,355 1,054,528 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 16.20 per share. 06 Oct 2025 138,602 1,504,959 - 16.2 2,245,352 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.45 per share. 06 Oct 2025 128,295 1,643,561 - 7.5 955,798 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.85 per share. 06 Oct 2025 10,307 1,515,266 - 15.9 163,366 Common Shares
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 16.15 per share. 06 Oct 2025 355,161 1,504,959 - 16.1 5,735,850 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 06 Oct 2025 180,859 1,860,120 - 3.8 696,307 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.45 per share. 06 Oct 2025 107,131 1,679,261 - 7.5 798,126 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.85 per share. 06 Oct 2025 67,171 1,572,130 - 15.8 1,064,660 Common Shares
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 16.34 per share. 06 Oct 2025 171,396 1,504,959 - 16.3 2,800,611 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 06 Oct 2025 19,141 1,676,355 - 3.9 73,693 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 06 Oct 2025 180,859 6,276,523 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 06 Oct 2025 107,131 128,295 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 06 Oct 2025 10,307 977,050 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 06 Oct 2025 19,141 6,457,382 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 06 Oct 2025 24,900 235,426 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 06 Oct 2025 67,171 987,357 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 06 Oct 2025 128,295 0 - - Stock Option (Right to Buy)
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.17 per share. 28 Sep 2025 2,341 389,508 - 15.2 35,513 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.04 per share. 20 Sep 2025 2,129 391,849 - 15.0 32,020 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Sep 2025 100,000 6,476,523 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Sep 2025 462,374 6,576,523 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Sep 2025 1,000,000 7,038,897 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 14.83 per share. 19 Sep 2025 611,000 1,504,959 - 14.8 9,061,130 Common Shares
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 15.01 per share. 19 Sep 2025 100,000 2,115,959 - 15.0 1,501,000 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 19 Sep 2025 100,000 2,532,141 - 3.9 385,000 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 19 Sep 2025 462,374 2,432,141 - 3.9 1,780,140 Common Shares
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 14.95 per share. 19 Sep 2025 683,818 1,969,767 - 14.9 10,223,079 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 19 Sep 2025 1,000,000 2,653,585 - 3.9 3,850,000 Common Shares
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 14.99 per share. 19 Sep 2025 316,182 2,215,959 - 15.0 4,739,568 Common Shares
Matthew Gline Director, CEO Purchase of securities on an exchange or from another person at price $ 15.07 per share. 18 Sep 2025 3,315 17,287,081 - 15.1 49,957 Common Shares
James C. Momtazee Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Sep 2025 33,726 33,726 - - Stock Option (Right to Buy)
James C. Momtazee Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Sep 2025 14,524 111,194 - 0 Common Shares
James C. Momtazee Director Other type of transaction at price $ 13.77 per share. 10 Sep 2025 3,282 107,912 - 13.8 45,193 Common Shares
Meghan M. Fitzgerald Director Other type of transaction at price $ 13.77 per share. 10 Sep 2025 937 42,963 - 13.8 12,902 Common Shares
Meghan M. Fitzgerald Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Sep 2025 33,726 33,726 - - Stock Option (Right to Buy)
Meghan M. Fitzgerald Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Sep 2025 14,524 43,900 - 0 Common Shares
Keith Manchester Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Sep 2025 14,524 1,948,403 - 0 Common Shares
Keith Manchester Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Sep 2025 33,726 33,726 - - Stock Option (Right to Buy)
Ilan Oren Director Other type of transaction at price $ 13.77 per share. 10 Sep 2025 2,043 117,162 - 13.8 28,132 Common Shares
Ilan Oren Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Sep 2025 14,524 119,205 - 0 Common Shares
Ilan Oren Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Sep 2025 33,726 33,726 - - Stock Option (Right to Buy)
Melissa B. Epperly Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Sep 2025 14,524 57,509 - 0 Common Shares
Melissa B. Epperly Director Other type of transaction at price $ 13.77 per share. 10 Sep 2025 1,661 55,848 - 13.8 22,872 Common Shares
Melissa B. Epperly Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Sep 2025 33,726 33,726 - - Stock Option (Right to Buy)
Daniel Gold Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Sep 2025 33,726 33,726 - - Stock Option (Right to Buy)
Daniel Gold Director Other type of transaction at price $ 13.77 per share. 10 Sep 2025 5,270 8,965,894 - 13.8 72,568 Common Shares
Daniel Gold Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Sep 2025 14,524 8,971,164 - 0 Common Shares
Vivek Ramaswamy Ten Percent Owner Sale of securities on an exchange or to another person at price $ 12.96 per share. 03 Sep 2025 385,816 35,508,359 - 13.0 5,000,175 Common Shares
Vivek Ramaswamy Ten Percent Owner Sale of securities on an exchange or to another person at price $ 12.92 per share. 03 Sep 2025 194,933 35,894,175 - 12.9 2,518,534 Common Shares
Vivek Ramaswamy Ten Percent Owner Sale of securities on an exchange or to another person at price $ 12.50 per share. 03 Sep 2025 1,195,000 36,089,108 - 12.5 14,937,500 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.94 per share. 28 Aug 2025 2,340 393,978 - 11.9 27,940 Common Shares
Eric Venker President & Immunovant CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.72 per share. 20 Aug 2025 7,051 1,653,585 - 11.7 82,638 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 20 Aug 2025 100,000 8,038,897 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 11.72 per share. 20 Aug 2025 100,000 1,653,585 - 11.7 1,172,000 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 20 Aug 2025 100,000 1,753,585 - 3.9 385,000 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.72 per share. 20 Aug 2025 1,235 396,318 - 11.7 14,474 Common Shares
Frank M. Torti President and Vant Chair Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Jul 2025 1,836,547 1,836,547 - 0 Common Shares
Frank M. Torti President and Vant Chair Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Jul 2025 11,900,000 13,736,547 - 0 Common Shares
Eric Venker President & Immunovant CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Jul 2025 198,413 1,660,636 - 0 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.35 per share. 28 Jul 2025 1,919 397,553 - 11.4 21,781 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 21 Jul 2025 100,000 8,138,897 - - Stock Option (Right to Buy)
Eric Venker President & Immunovant CEO Sale of securities on an exchange or to another person at price $ 11.52 per share. 21 Jul 2025 100,000 1,462,223 - 11.5 1,152,000 Common Shares
Eric Venker President & Immunovant CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 21 Jul 2025 100,000 1,562,223 - 3.9 385,000 Common Shares
James C. Momtazee Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Jul 2025 1,201 96,911 - 0 Common Shares
James C. Momtazee Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.65 per share. 17 Jul 2025 241 96,670 - 11.7 2,808 Common Shares
Ilan Oren Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.65 per share. 17 Jul 2025 115 104,681 - 11.7 1,340 Common Shares
Ilan Oren Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Jul 2025 2,296 104,796 - 0 Common Shares
Melissa B. Epperly Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Jul 2025 1,609 42,985 - 0 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.39 per share. 28 Jun 2025 1,653 399,472 - 11.4 18,828 Common Shares
Keith Manchester Director Other type of transaction at price $ 0.00 per share. 25 Jun 2025 6,837,266 0 - 0 Common Shares
Keith Manchester Director Other type of transaction at price $ 0.00 per share. 25 Jun 2025 3,176,245 19,347,727 - 0 Common Shares
Keith Manchester Director Other type of transaction at price $ 0.00 per share. 25 Jun 2025 6,205,368 8,441,428 - 0 Common Shares
Keith Manchester Director Other type of transaction at price $ 0.00 per share. 25 Jun 2025 1,170,646 1,592,480 - 0 Common Shares
Daniel Gold Director Other type of transaction at price $ 0.00 per share. 25 Jun 2025 1,170,646 1,592,480 - 0 Common Shares
Daniel Gold Director Other type of transaction at price $ 0.00 per share. 25 Jun 2025 55,443 0 - 0 Common Shares
Daniel Gold Director Other type of transaction at price $ 0.00 per share. 25 Jun 2025 19,311,790 0 - 0 Common Shares
Daniel Gold Director Other type of transaction at price $ 0.00 per share. 25 Jun 2025 6,837,266 0 - 0 Common Shares
Daniel Gold Director Other type of transaction at price $ 0.00 per share. 25 Jun 2025 3,176,245 19,347,727 - 0 Common Shares
Daniel Gold Director Other type of transaction at price $ 0.00 per share. 25 Jun 2025 6,205,368 8,441,428 - 0 Common Shares
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 20 Jun 2025 100,000 8,238,897 - - Stock Option (Right to Buy)
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 20 Jun 2025 100,000 1,562,223 - 3.9 385,000 Common Shares
Eric Venker President & COO Sale of securities on an exchange or to another person at price $ 11.45 per share. 20 Jun 2025 100,000 1,462,223 - 11.5 1,145,000 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.45 per share. 20 Jun 2025 1,503 399,056 - 11.4 17,209 Common Shares
Vivek Ramaswamy Ten Percent Owner Sale of securities on an exchange or to another person at price $ 11.46 per share. 18 Jun 2025 577,007 37,284,108 - 11.5 6,612,500 Common Shares
Vivek Ramaswamy Ten Percent Owner Sale of securities on an exchange or to another person at price $ 11.45 per share. 18 Jun 2025 565,266 37,861,115 - 11.5 6,472,296 Common Shares
Vivek Ramaswamy Ten Percent Owner Sale of securities on an exchange or to another person at price $ 11.34 per share. 04 Jun 2025 547,430 38,627,181 - 11.3 6,207,856 Common Shares
Vivek Ramaswamy Ten Percent Owner Sale of securities on an exchange or to another person at price $ 11.19 per share. 04 Jun 2025 200,800 38,426,381 - 11.2 2,246,952 Common Shares
Eric Venker President & COO Sale of securities on an exchange or to another person at price $ 11.22 per share. 02 Jun 2025 566,278 1,462,223 - 11.2 6,353,639 Common Shares
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 02 Jun 2025 785,026 8,338,897 - - Stock Option (Right to Buy)
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 02 Jun 2025 600,000 9,123,923 - - Stock Option (Right to Buy)
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 02 Jun 2025 600,000 1,677,197 - 3.9 2,310,000 Common Shares
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 02 Jun 2025 785,026 2,028,501 - 3.8 3,022,350 Common Shares
Eric Venker President & COO Sale of securities on an exchange or to another person at price $ 11.07 per share. 02 Jun 2025 433,722 1,243,475 - 11.1 4,801,303 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.62 per share. 28 May 2025 1,653 400,559 - 10.6 17,555 Common Shares
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 20 May 2025 100,000 9,723,923 - - Stock Option (Right to Buy)
Eric Venker President & COO Sale of securities on an exchange or to another person at price $ 10.95 per share. 20 May 2025 100,000 1,077,197 - 11.0 1,095,000 Common Shares
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 20 May 2025 100,000 1,177,197 - 3.9 385,000 Common Shares
Eric Venker President & COO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.04 per share. 20 May 2025 39,148 1,077,197 - 11.0 432,194 Common Shares
Matthew Gline Director, CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.04 per share. 20 May 2025 10,945 17,283,766 - 11.0 120,833 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.04 per share. 20 May 2025 3,487 402,212 - 11.0 38,496 Common Shares
Vivek Ramaswamy Ten Percent Owner Sale of securities on an exchange or to another person at price $ 11.18 per share. 06 May 2025 625,000 39,174,611 - 11.2 6,987,500 Common Shares
Vivek Ramaswamy Ten Percent Owner Sale of securities on an exchange or to another person at price $ 11.47 per share. 06 May 2025 273,959 39,799,611 - 11.5 3,142,310 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.19 per share. 28 Apr 2025 1,653 405,699 - 11.2 18,497 Common Shares
Richard Pulik CFO Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Apr 2025 141,464 407,352 - 0 Common Shares
Richard Pulik CFO Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Apr 2025 180,413 180,413 - - Stock Option (Right to Buy)
Eric Venker President & COO Sale of securities on an exchange or to another person at price $ 10.22 per share. 20 Apr 2025 100,000 1,116,345 - 10.2 1,022,000 Common Shares
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 20 Apr 2025 100,000 9,823,923 - - Stock Option (Right to Buy)
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 20 Apr 2025 100,000 1,216,345 - 3.9 385,000 Common Shares
Eric Venker President & COO Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.15 per share. 20 Apr 2025 10,945 1,116,345 - 10.2 111,092 Common Shares
Matthew Gline Director, CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.15 per share. 20 Apr 2025 10,945 17,294,711 - 10.2 111,092 Common Shares
James C. Momtazee Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.15 per share. 17 Apr 2025 276 95,710 - 10.1 2,801 Common Shares
James C. Momtazee Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Apr 2025 1,379 95,986 - 0 Common Shares
Ilan Oren Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.16 per share. 17 Apr 2025 64 102,500 - 10.2 650 Common Shares
Ilan Oren Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Apr 2025 2,635 102,564 - 0 Common Shares
Melissa B. Epperly Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Apr 2025 1,847 41,376 - 0 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.38 per share. 28 Mar 2025 1,653 265,888 - 10.4 17,158 Common Shares
Eric Venker President & COO Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.97 per share. 20 Mar 2025 10,945 874,979 - 11.0 120,067 Common Shares
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 20 Mar 2025 602,311 9,923,923 - - Stock Option (Right to Buy)
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 20 Mar 2025 400,000 10,526,234 - - Stock Option (Right to Buy)
Eric Venker President & COO Sale of securities on an exchange or to another person at price $ 10.82 per share. 20 Mar 2025 434,478 1,127,290 - 10.8 4,701,052 Common Shares
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 20 Mar 2025 602,311 1,561,768 - 3.8 2,318,897 Common Shares
Eric Venker President & COO Sale of securities on an exchange or to another person at price $ 11.06 per share. 20 Mar 2025 315,522 959,457 - 11.1 3,489,673 Common Shares
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 20 Mar 2025 400,000 1,274,979 - 3.9 1,540,000 Common Shares
Matthew Gline Director, CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.97 per share. 20 Mar 2025 10,945 17,305,656 - 11.0 120,067 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.97 per share. 20 Mar 2025 1,504 267,541 - 11.0 16,499 Common Shares
Jennifer Humes Chief Accounting Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 20 Mar 2025 115,108 115,108 - - Stock Option (Right to Buy)
Jennifer Humes Chief Accounting Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 20 Mar 2025 112,255 112,255 - 0 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.74 per share. 28 Feb 2025 1,635 269,045 - 10.7 17,560 Common Shares
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 20 Feb 2025 100,000 996,869 - 3.9 385,000 Common Shares
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 20 Feb 2025 100,000 10,926,234 - - Stock Option (Right to Buy)
Eric Venker President & COO Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.72 per share. 20 Feb 2025 10,945 885,924 - 10.7 117,330 Common Shares
Eric Venker President & COO Sale of securities on an exchange or to another person at price $ 10.65 per share. 20 Feb 2025 100,000 896,869 - 10.7 1,065,000 Common Shares
Rakhi Kumar Chief Accounting Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.72 per share. 20 Feb 2025 958 162,306 - 10.7 10,270 Common Shares
Matthew Gline Director, CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.72 per share. 20 Feb 2025 10,945 17,316,601 - 10.7 117,330 Common Shares
Rakhi Kumar Chief Accounting Officer Sale of securities on an exchange or to another person at price $ 10.43 per share. 13 Feb 2025 227,500 163,264 - 10.4 2,372,825 Common Shares
Rakhi Kumar Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 13 Feb 2025 187,500 390,764 - 3.9 721,875 Common Shares
Rakhi Kumar Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Feb 2025 187,500 312,500 - - Stock Option (Right to Buy)
Eric Venker President & COO Sale of securities on an exchange or to another person at price $ 10.42 per share. 12 Feb 2025 218,041 896,869 - 10.4 2,271,987 Common Shares
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 12 Feb 2025 300,000 11,026,234 - - Stock Option (Right to Buy)
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 12 Feb 2025 300,000 11,326,234 - - Stock Option (Right to Buy)
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 12 Feb 2025 300,000 1,032,294 - 3.9 1,155,000 Common Shares
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 12 Feb 2025 300,000 1,114,910 - 3.9 1,155,000 Common Shares
Eric Venker President & COO Sale of securities on an exchange or to another person at price $ 10.53 per share. 12 Feb 2025 217,384 732,294 - 10.5 2,289,054 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.15 per share. 28 Jan 2025 1,896 270,680 - 11.1 21,140 Common Shares
Vivek Ramaswamy Ten Percent Owner Gift of securities by or to the insider at price $ 0.00 per share. 23 Jan 2025 13,357,857 13,357,857 - 0 Common Shares
Vivek Ramaswamy Ten Percent Owner Gift of securities by or to the insider at price $ 0.00 per share. 23 Jan 2025 13,357,857 40,073,570 - 0 Common Shares
James C. Momtazee Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.21 per share. 23 Jan 2025 306 94,607 - 11.2 3,430 Common Shares
James C. Momtazee Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Jan 2025 1,248 94,913 - 0 Common Shares
Ilan Oren Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.21 per share. 23 Jan 2025 313 99,929 - 11.2 3,509 Common Shares
Ilan Oren Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Jan 2025 2,386 100,242 - 0 Common Shares
Melissa B. Epperly Director Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.21 per share. 23 Jan 2025 180 39,529 - 11.2 2,018 Common Shares
Melissa B. Epperly Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Jan 2025 1,672 39,709 - 0 Common Shares
Eric Venker President & COO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.15 per share. 20 Jan 2025 8,682 732,294 - 11.1 96,804 Common Shares
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 20 Jan 2025 100,000 832,294 - 3.9 385,000 Common Shares
Eric Venker President & COO Sale of securities on an exchange or to another person at price $ 11.28 per share. 20 Jan 2025 100,000 732,294 - 11.3 1,128,000 Common Shares
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 20 Jan 2025 100,000 11,626,234 - - Stock Option (Right to Buy)
Rakhi Kumar Chief Accounting Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.15 per share. 20 Jan 2025 1,057 203,264 - 11.2 11,786 Common Shares
Matthew Gline Director, CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.15 per share. 20 Jan 2025 11,623 17,327,546 - 11.1 129,596 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.80 per share. 28 Dec 2024 1,896 272,576 - 11.8 22,373 Common Shares
Eric Venker President & COO Sale of securities on an exchange or to another person at price $ 11.54 per share. 27 Dec 2024 177,704 740,976 - 11.5 2,050,704 Common Shares
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 27 Dec 2024 250,000 918,680 - 3.9 962,500 Common Shares
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 27 Dec 2024 250,000 11,976,234 - - Stock Option (Right to Buy)
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 27 Dec 2024 250,000 845,580 - 3.9 962,500 Common Shares
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 27 Dec 2024 250,000 11,726,234 - - Stock Option (Right to Buy)
Eric Venker President & COO Sale of securities on an exchange or to another person at price $ 11.82 per share. 27 Dec 2024 176,900 668,680 - 11.8 2,090,958 Common Shares
Mayukh Sukhatme Director, Pres&Chief Investment Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 23 Dec 2024 185,946 19,022,493 - 3.8 715,892 Common Shares
Mayukh Sukhatme Director, Pres&Chief Investment Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 23 Dec 2024 10,796 18,847,343 - 3.9 41,565 Common Shares
Mayukh Sukhatme Director, Pres&Chief Investment Officer Sale of securities on an exchange or to another person at price $ 12.00 per share. 23 Dec 2024 10,796 18,836,547 - 12 129,552 Common Shares
Mayukh Sukhatme Director, Pres&Chief Investment Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 23 Dec 2024 689,495 15,224,363 - - Stock Option (Right to Buy)
Mayukh Sukhatme Director, Pres&Chief Investment Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 23 Dec 2024 185,946 15,913,858 - - Stock Option (Right to Buy)
Mayukh Sukhatme Director, Pres&Chief Investment Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 23 Dec 2024 10,796 16,099,804 - - Stock Option (Right to Buy)
Mayukh Sukhatme Director, Pres&Chief Investment Officer Sale of securities on an exchange or to another person at price $ 12.01 per share. 23 Dec 2024 689,495 18,836,547 - 12.0 8,280,835 Common Shares
Mayukh Sukhatme Director, Pres&Chief Investment Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 23 Dec 2024 689,495 19,526,042 - 3.9 2,654,556 Common Shares
Mayukh Sukhatme Director, Pres&Chief Investment Officer Sale of securities on an exchange or to another person at price $ 12.00 per share. 23 Dec 2024 185,946 18,836,547 - 12 2,231,352 Common Shares
Eric Venker President & COO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.57 per share. 20 Dec 2024 10,945 595,580 - 11.6 126,634 Common Shares
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 20 Dec 2024 100,000 12,226,234 - - Stock Option (Right to Buy)
Eric Venker President & COO Sale of securities on an exchange or to another person at price $ 11.49 per share. 20 Dec 2024 100,000 595,580 - 11.5 1,149,000 Common Shares
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 20 Dec 2024 100,000 695,580 - 3.9 385,000 Common Shares
Rakhi Kumar Chief Accounting Officer 20 Dec 2024 3,087 204,321 - 11.6 35,717 Common Shares
Matthew Gline Director, CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.57 per share. 20 Dec 2024 10,945 17,339,169 - 11.6 126,634 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.57 per share. 20 Dec 2024 2,129 274,472 - 11.6 24,633 Common Shares
Mayukh Sukhatme Director, Pres&Chief Investment Officer Sale of securities on an exchange or to another person at price $ 12.05 per share. 18 Dec 2024 412,584 18,836,547 - 12.0 4,971,637 Common Shares
Mayukh Sukhatme Director, Pres&Chief Investment Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 18 Dec 2024 412,584 16,110,600 - - Stock Option (Right to Buy)
Mayukh Sukhatme Director, Pres&Chief Investment Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 18 Dec 2024 412,584 19,249,131 - 3.8 1,588,448 Common Shares
Mayukh Sukhatme Director, Pres&Chief Investment Officer Other type of transaction at price $ 12.21 per share. 03 Dec 2024 3,651,985 18,836,547 - 12.2 44,572,477 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.69 per share. 28 Nov 2024 2,341 276,601 - 12.7 29,707 Common Shares
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 20 Nov 2024 100,000 706,525 - 3.9 385,000 Common Shares
Eric Venker President & COO Sale of securities on an exchange or to another person at price $ 11.32 per share. 20 Nov 2024 100,000 606,525 - 11.3 1,132,000 Common Shares
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 20 Nov 2024 100,000 12,326,234 - - Stock Option (Right to Buy)
Eric Venker President & COO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.49 per share. 20 Nov 2024 10,945 606,525 - 11.5 125,758 Common Shares
Rakhi Kumar Chief Accounting Officer 20 Nov 2024 958 207,408 - 11.5 11,007 Common Shares
Matthew Gline Director, CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.49 per share. 20 Nov 2024 10,945 17,350,114 - 11.5 125,758 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.84 per share. 28 Oct 2024 2,341 278,942 - 11.8 27,717 Common Shares
James C. Momtazee Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Oct 2024 1,231 93,665 - 0 Common Shares
Ilan Oren Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Oct 2024 2,303 97,856 - 0 Common Shares
Melissa B. Epperly Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Oct 2024 1,613 38,037 - 0 Common Shares
Eric Venker President & COO Sale of securities on an exchange or to another person at price $ 11.65 per share. 20 Oct 2024 100,000 617,470 - 11.7 1,165,000 Common Shares
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 20 Oct 2024 100,000 12,426,234 - - Stock Option (Right to Buy)
Eric Venker President & COO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 20 Oct 2024 100,000 717,470 - 3.9 385,000 Common Shares
Eric Venker President & COO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.92 per share. 20 Oct 2024 10,945 617,470 - 11.9 130,464 Common Shares
Rakhi Kumar Chief Accounting Officer 20 Oct 2024 956 208,366 - 11.9 11,396 Common Shares
Matthew Gline Director, CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.92 per share. 20 Oct 2024 10,945 17,361,059 - 11.9 130,464 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.48 per share. 28 Sep 2024 2,340 281,283 - 11.5 26,863 Common Shares
Keith Manchester Director Sale of securities on an exchange or to another person at price $ 11.63 per share. 24 Sep 2024 368,052 1,412,126 - 11.6 4,278,605 Common Shares
Keith Manchester Director Sale of securities on an exchange or to another person at price $ 11.77 per share. 24 Sep 2024 134,948 1,277,178 - 11.8 1,587,704 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 11.77 per share. 24 Sep 2024 991,593 4,731,830 - 11.8 11,666,389 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 11.77 per share. 24 Sep 2024 50,000 23,055,358 - 11.8 588,500 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 11.77 per share. 24 Sep 2024 365,551 1,713,508 - 11.8 4,300,817 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 11.82 per share. 24 Sep 2024 876,000 22,179,358 - 11.8 10,354,320 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 11.62 per share. 24 Sep 2024 577,186 2,079,059 - 11.6 6,709,787 Common Shares
Daniel Gold Director Sale of securities on an exchange or to another person at price $ 11.63 per share. 24 Sep 2024 1,565,670 5,723,423 - 11.6 18,200,914 Common Shares
Eric Venker President & COO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.97 per share. 20 Sep 2024 10,945 628,415 - 12.0 131,012 Common Shares
Rakhi Kumar Chief Accounting Officer 20 Sep 2024 3,087 209,322 - 12.0 36,951 Common Shares
Rakhi Kumar Chief Accounting Officer 20 Sep 2024 250,000 459,322 - 3.9 962,500 Common Shares
Rakhi Kumar Chief Accounting Officer 20 Sep 2024 250,000 500,000 - - Stock Option (Right to Buy)
Rakhi Kumar Chief Accounting Officer 20 Sep 2024 250,000 209,322 - 11.9 2,972,500 Common Shares
Matthew Gline Director, CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.97 per share. 20 Sep 2024 10,945 18,303,800 - 12.0 131,012 Common Shares
Matthew Gline Director, CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 20 Sep 2024 1,550,000 14,973,184 - - Stock Option (Right to Buy)
Matthew Gline Director, CEO Other type of transaction at price $ 11.97 per share. 20 Sep 2024 498,539 17,372,004 - 12.0 5,967,512 Common Shares
Matthew Gline Director, CEO Sale of securities on an exchange or to another person at price $ 11.79 per share. 20 Sep 2024 1,983,257 17,870,543 - 11.8 23,382,600 Common Shares
Matthew Gline Director, CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. 20 Sep 2024 1,550,000 19,853,800 - 3.9 5,967,500 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.97 per share. 20 Sep 2024 2,129 283,623 - 12.0 25,484 Common Shares
James C. Momtazee Director Other type of transaction at price $ 12.12 per share. 12 Sep 2024 3,056 92,434 - 12.1 37,039 Common Shares
Meghan M. Fitzgerald Director Other type of transaction at price $ 12.12 per share. 12 Sep 2024 894 29,376 - 12.1 10,835 Common Shares
Ilan Oren Director Other type of transaction at price $ 12.12 per share. 12 Sep 2024 3,487 95,553 - 12.1 42,262 Common Shares
Melissa B. Epperly Director Other type of transaction at price $ 12.12 per share. 12 Sep 2024 4,245 36,424 - 12.1 51,449 Common Shares
Daniel Gold Director Other type of transaction at price $ 12.12 per share. 12 Sep 2024 2,599 7,289,093 - 12.1 31,500 Common Shares
James C. Momtazee Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Sep 2024 27,894 27,894 - - Stock Option (Right to Buy)
James C. Momtazee Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Sep 2024 16,406 95,490 - 0 Common Shares
Meghan M. Fitzgerald Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Sep 2024 16,406 30,270 - 0 Common Shares
Meghan M. Fitzgerald Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Sep 2024 27,894 27,894 - - Stock Option (Right to Buy)
Keith Manchester Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Sep 2024 27,894 27,894 - - Stock Option (Right to Buy)
Keith Manchester Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Sep 2024 16,406 1,780,178 - 0 Common Shares
Ilan Oren Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Sep 2024 16,406 99,040 - 0 Common Shares
Ilan Oren Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Sep 2024 27,894 27,894 - - Stock Option (Right to Buy)
Melissa B. Epperly Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Sep 2024 27,894 27,894 - - Stock Option (Right to Buy)
Melissa B. Epperly Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Sep 2024 16,406 40,669 - 0 Common Shares
Daniel Gold Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Sep 2024 27,894 27,894 - - Stock Option (Right to Buy)
Daniel Gold Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 10 Sep 2024 16,406 7,291,692 - 0 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.00 per share. 28 Aug 2024 2,341 285,752 - 12 28,092 Common Shares
Eric Venker President & COO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.48 per share. 20 Aug 2024 10,947 639,360 - 11.5 125,672 Common Shares
Rakhi Kumar Chief Accounting Officer 20 Aug 2024 958 212,409 - 11.5 10,998 Common Shares
Matthew Gline Director, CEO Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.48 per share. 20 Aug 2024 10,947 18,314,745 - 11.5 125,672 Common Shares
Richard Pulik CFO Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.80 per share. 28 Jul 2024 2,341 288,093 - 10.8 25,283 Common Shares
Eric Venker President & COO Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Jul 2024 409,000 409,000 - - Stock Option (Right to Buy)
Eric Venker President & COO Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Jul 2024 204,000 650,307 - 0 Common Shares
Matthew Gline Director, CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Jul 2024 2,754,821 3,875,692 - 0 Common Shares
Matthew Gline Director, CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Jul 2024 14,450,000 18,325,692 - 0 Common Shares
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures
Screeners based on Insider Trading and SAST parameters